Median Technologies (Euronext Growth – ALMDT) is proud to announce the publication of an initiation report by Portzamparc Groupe BNP Paribas, a preeminent French financial services provider expertly serving both individual and institutional investors, as well as corporate and institutional customers.
Portzamparc Groupe BNP Paribas has issued a bullish Strong Buy recommendation for a particular stock in its newest initiation report published on July 20, 2023 – signaling their strong belief in the immense potential of that stock.
About Portzamparc Groupe BNP Paribas
As the European leader in mid-cap transactions, Portzamparc offers unparalleled expertise in the stock market, third-party asset management, and market operations for SMEs/ETIs. With a transaction volume of nearly €9 billion and €4 billion in assets under management, Portzamparc offers exceptional support to private and institutional investors, outstanding financial analysis, and undisputed leadership in IPOs.
About Median Technologies
At Median Technologies, we are revolutionizing healthcare with innovative imaging solutions and services. Our cutting-edge Artificial Intelligence technologies are revolutionizing the accuracy of diagnosis and treatment of various cancers and metabolic diseases in their early stages.
Our iCRO and iBiopsy software offer biopharmaceutical companies and healthcare providers the ability to identify novel treatments and diagnose patients more accurately and in a timely manner, allowing us to make the world healthier and stronger.
Median, a French company founded in 2002 with a presence in Sophia-Antipolis, the US and Shanghai, is making waves in the industry. Boasting the label of “Innovative Company” from the BPI, along with its listing on Euronext Growth market (FR0011049824– ticker: ALMDT), Median has become eligible for French SME equity savings plan scheme (PEA-PME) – an accomplishment that speaks to its commitment and dedication.